GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Dermata Therapeutics Inc (NAS:DRMA) » Definitions » GF Value

DRMA (Dermata Therapeutics) GF Value : $0.00 (As of Mar. 26, 2025)


View and export this data going back to 2021. Start your Free Trial

What is Dermata Therapeutics GF Value?

As of today (2025-03-26), Dermata Therapeutics's share price is $1.35. Dermata Therapeutics's GF Value is $0.00. Therefore, Dermata Therapeutics's Price-to-GF-Value for today is . Based on the relationship between the current stock price and the GF Value, GuruFocus believes Dermata Therapeutics is Not Valued.

The GF Value represents the intrinsic value of a stock, determined using GuruFocus' proprietary methodology. The GF Value Line on our stock Summary page provides an estimate of the stock’s fair-trading value.

To calculate this value, GuruFocus follows these steps:

  1. We analyze historical correlations between the stock price and key business performance metrics, such as revenue, earnings, cash flow, and book value.
  2. We identify the metrics that have the strongest historical correlation with the stock price and determine the historical multiples at which the stock has traded relative to these metrics.
  3. Using these historical multiples as a reference, we estimate the stock's fair value while accounting for future business growth. Adjustments may be made based on the company’s past returns and growth trends.

GuruFocus believes that the GF Value Line represents the fair value at which a stock should trade. Stock prices typically fluctuate around this line. If a stock’s price is significantly above the GF Value Line, it is considered overvalued, and its future returns are likely to be lower. Conversely, if the stock price is significantly below the GF Value Line, its future returns are likely to be higher.

Please note that "Possible Value Trap, Think Twice" applies to companies that appear significantly undervalued but are either experiencing a long-term business decline or facing financial distress.


Dermata Therapeutics  (NAS:DRMA) GF Value Explanation

Based on the relationship between the current stock price and the GF Value, GuruFocus provides the following 6 ratings:

Posssible Evaluations All-in-One Screener Examples (2)
Possible Value Trap, Think Twice (1)Predictable Companies that possibly be Value Traps
Significantly OvervaluedPredictable Companies which are Significantly Overvalued
Modestly OvervaluedPredictable Companies which are Modestly Overvalued
Fairly ValuedPredictable High Quality Companies which are Fairly Valued
Modestly Undervalued (3)Predictable High Quality Companies which are Modestly Undervalued
Significantly Undervalued (3)Predictable High Quality Companies which are Significantly Undervalued

(1) "Possible Value Trap, Think Twice" applies to companies that appear significantly undervalued but are either experiencing a long-term business decline or facing financial distress.

(2) These are some simple examples. You can access our GF Valuation filter under All-in-One Screener’s Fundamental tab, and Price-to-GF-Value filter under Valuation Ratio tab and set your own criteria.

(3) A sufficient margin of safety exists only when the stock is undervalued.

Dermata Therapeutics's Price-to-GF-Value for today is calculated as

Price-to-GF-Value=Share Price/GF Value
=1.35/0.00
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Dermata Therapeutics GF Value Related Terms

Thank you for viewing the detailed overview of Dermata Therapeutics's GF Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Dermata Therapeutics Business Description

Traded in Other Exchanges
N/A
Address
3525 Del Mar Heights Road, Suite No. 322, San Diego, CA, USA, 92130
Dermata Therapeutics Inc is a clinical-stage medical dermatology company focused on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. Its two product candidates, DMT310 and DMT410, incorporate its proprietary, multifaceted, Spongilla technology to topically treat a variety of dermatological conditions. Its Spongilla technology platform will enable to develop and formulate singular and combination products that are able to target topical delivery of chemical compounds into the dermis for maximum treatment effect for a variety of inflammatory skin diseases.
Executives
Brittany Bradrick director C/O DERMATA THERAPEUTICS, INC., 3525 DEL MAR HEIGHTS RD., #322, SAN DIEGO CA 92130
Gerald T Proehl 10 percent owner, officer: Pres., CEO and Chairman
Van Hoose Kyri K. officer: Chief Financial Officer C/O TURNING POINT THERAPEUTICS, INC., 10628 SCIENCE CENTER DRIVE, SUITE 200, SAN DIEGO CA 92121
Mary Fisher director C/O ACORDA THERAPEUTICS, INC., 15 SKYLINE DRIVE, HAWTHORNE NY 10532
David F Hale director 1042-B NORTH EL CAMINO REAL, SUITE 430, ENCINITAS CA 92024
Steven J Mento director C/O SANGAMO BIOSCIENCES, INC., 501 CANAL BLVD SUITE A-100, RICHMOND CA 94804
Wendell Wierenga director C/O CIPHERGEN BIOSYSTEMS INC, 6611 DUMBARTON CIRCLE, FREMONT CA 94555
Kathleen D. Scott director C/O CONATUS PHARMACEUTICALS INC., 16745 WEST BERNARDO DRIVE, SUITE 200, SAN DIEGO CA 92127
Thomas Insley officer: Chief Financial Officer SKINMEDICA, INC., 5909 SEA LION PLACE, SUITE H, CARLSBAD CA 92010
Bedoya-toro Munera Maria E officer: Senior VP 10590 WEST OCEAN AIR DRIVE, SUITE 200, SAN DIEGO CA 92130
Andrew Seth Sandler director 1301 2ND AVE, SEATTLE WA 98101
Christopher J. Nardo officer: Senior VP, Development C/O DERMATA THERAPEUTICS, INC., 3525 DEL MAR HEIGHTS RD., #322, SAN DIEGO CA 92130
Proehl Investment Ventures Llc 10 percent owner C/O DERMATA THERAPEUTICS, INC., 3525 DEL MAR HEIGHTS RD., #332, SAN DIEGO CA 92130